Chargement en cours...
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
BACKGROUND: Several cancer types harbor alterations in the gene encoding AT-Rich Interactive Domain-containing protein 1A (ARID1A), but there are no approved therapies to address these alterations. Recent studies have shown that ARID1A deficiency compromises mismatch repair proteins. Herein, we anal...
Enregistré dans:
| Publié dans: | J Immunother Cancer |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMJ Publishing Group
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7057434/ https://ncbi.nlm.nih.gov/pubmed/32111729 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000438 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|